Approval · Notice of Compliance 17019 · 2015
VAN-ZOLMITRIPTAN: Notice of Compliance 17019
Issued June 22, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17019
- Date
- June 22, 2015
- Company
- Vanc Pharmaceuticals IncRichmond, British Columbia, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
- Canadian reference product
- ZOMIG (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VAN-ZOLMITRIPTAN | 02438771 | Cancelled Pre Market |
Medicinal ingredients
- ZOLMITRIPTAN 2.5 MG per TAB